Although GK-GKRP disruptors exhibited low hypoglycemic risk [17], potential hypertriglyceridemia due to excess liver glycogen deposition and de novo lipogenesis are significant concerns [19, 20]. This evidence concerns the gene GCKR and hypertriglyceridemia.